Sales & Marketing News | pharmaphorum

News

Bayer CEO says recovery on track as key drug products shine

Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales, but lower profits for the second quarter.

News

Mallinckrodt sells Therakos unit on at a discount

Ireland-headquartered pharma group Mallinckrodt has agreed to divest its subsidiary Therakos to private equity firm CVC Capital Partners for $925 million, well below the $1.33 billion it pa

News

Actinium's radioligand filing plans scuppered by FDA

Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radiol

News

FDA panel backs Zevra's arimoclomol, after earlier rejection

An FDA advisory committee has recommended approval of Zevra Therapeutics' arimoclomol for the ultra-rare disorder Niemann-Pick disease, three years after the regulator rejected the drug.

News

GSK bags sought-after Jemperli okay in endometrial cancer

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions f

News

FDA clears Adaptimmune T-cell therapy for soft tissue cancer

The FDA has given accelerated approval to a groundbreaking T cell-based therapy from Adaptimmune for synovial sarcoma, becoming the first new treatment for the rare soft tissue cancer in mo

Bayer CEO says recovery on track as key drug products shine

Mallinckrodt sells Therakos unit on at a discount

Actinium's radioligand filing plans scuppered by FDA

FDA panel backs Zevra's arimoclomol, after earlier rejection

GSK bags sought-after Jemperli okay in endometrial cancer

FDA clears Adaptimmune T-cell therapy for soft tissue cancer

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks